Search for: "In Re Hedges" Results 601 - 620 of 2,367
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
7 Apr 2017, 6:00 am
Kohn, Cleary Gottlieb Steen & Hamilton LLP, on Tuesday, April 4, 2017 Tags: Boards of Directors, Delaware law, Disclosure, Executive Compensation, Fiduciary duties, Hedge funds, Institutional Investors, Management, Proxy access, Settlements, Shareholder activism, Shareholder voting Regulating Robo Advice Across the Financial Services Industry Posted by Tom Baker, University of Pennsylvania, and Benedict C.G. [read post]
4 Apr 2017, 9:30 am by J. Dana Stuster
Erdogan “wavers and hedges his bets—from turning to Russia and now looking to rekindle Turkey’s ties with Israel to counter Iran in Syria—but his inclination to play the anti-American card when expedient should not be lost on the Trump national security team,” they write. [read post]
31 Mar 2017, 1:35 pm by Kelly Phillips Erb
In other words, we can’t say we’re putting the federal government on a diet, keep eating and skip out on the run altogether. [read post]
29 Mar 2017, 5:09 am by SHG
David Meyer-Lindenberg crosses Chairman of the Board of Cato Institute, Robert Levy. [read post]
21 Mar 2017, 6:17 pm by Kelly Phillips Erb
If you’re wondering whether you can claim wardrobe expenses or whether to deduct a capital loss, you won’t want to miss it. [read post]
17 Mar 2017, 6:00 am by Doug Cornelius
This article suggests that a novel market mechanism, a “super hedge fund,” would maintain the benefits of hedge fund activism, while curbing its downsides. [read post]
16 Mar 2017, 3:00 am by John Jenkins
He also speaks well of an alternative approach that at least one leading hedge fund has already adopted: Evidence suggests that hedge fund activism is perhaps most valuable when it involves a somewhat rougher form of relationship investing of the kind for which Warren Buffet is known. [read post]
9 Mar 2017, 11:23 pm by nedaj
Marijuana / Cannabis Hedge Funds – we recently wrote a post about the legal and operational issues for hedge fund managers in the cannabis space. [read post]
3 Mar 2017, 6:16 am
., on Friday, February 24, 2017 Tags: Clawbacks, Compensation disclosure, Compensation ratios, Disclosure, Dodd-Frank Act, Equity-based compensation, Executive Compensation, Firm performance, Hedging, Incentives, ISS, Management, Pay for performance, Say on pay, Securities regulation, Stock options Private Funds Year in Review and 2017 Outlook Posted by Ari M. [read post]
24 Feb 2017, 5:35 am
Haas, Hunton & Williams LLP, on Tuesday, February 21, 2017 Tags: Appraisal rights, Business judgment rule, Conflicts of interest, Delaware cases, Delaware law, Fairness review, Fiduciary duties, In re Trulia, Institutional Investors, Merger litigation, Mergers & acquisitions The Activist Investing Annual Review 2017 Posted by Josh Black, Activist Insight, on Tuesday, February 21, 2017 Tags: Boards of Directors, Hedge funds, International governance, Mergers &… [read post]
17 Feb 2017, 5:40 am
Liekefett, Vinson & Elkins LLP, on Thursday, February 16, 2017 Tags: Antitakeover, Charter & bylaws, Director nominations, Engagement, Hedge funds, Management, Poison pills, Proxy contests, Proxy fights, Schedule 13D, Shareholder activism, Shareholder elections, Small firms, Takeover defenses [read post]
13 Feb 2017, 4:45 am by Jon Hyman
  “Overall, there needs to be a re-evaluation of the costs and benefits,” Lipnic said. [read post]
13 Feb 2017, 4:45 am by Jon Hyman
  “Overall, there needs to be a re-evaluation of the costs and benefits,” Lipnic said. [read post]
10 Feb 2017, 9:46 pm by Mark Summerfield
On 30 October 2008, the US Court of Appeals for the Federal Circuit (CAFC) handed down its en banc decision in In re Bilski, affirming the rejection of patent claims directed to a method of hedging risks in commodities trading. [read post]
10 Feb 2017, 2:05 pm by Rebecca Tushnet
  Collective funds to get more revenue into the pockets of artists—a hedge fund for artists. [read post]
8 Feb 2017, 2:18 pm by Patrick A. Malone
Patients say they’re aggravated that the various Big Pharma players appear to work in concert to send insulin’s price, in lockstep, skyrocketing. [read post]